Recursion Pharmaceuticals (RXRX) P/E Ratio
P/E Ratio as of Oct 15, 2025: -3.80
Average-2.94
Median-2.83
Minimum-3.80
Maximum-2.59
-3.80
Past Month-1.13 (42.32%)
The P/E ratio for Recursion Pharmaceuticals (RXRX) is -3.80 as of Oct 15, 2025. This represents a increase of 6.74% compared to its 12-month average P/E ratio of -3.56. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
Recursion Pharmaceuticals P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Recursion Pharmaceuticals’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Recursion Pharmaceuticals to industry peers.
Recursion Pharmaceuticals P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Recursion Pharmaceuticals’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Recursion Pharmaceuticals to industry peers.
Recursion Pharmaceuticals (RXRX) P/E Ratio Insights
See Recursion Pharmaceuticals’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in Recursion Pharmaceuticals (RXRX)
Order type
Buy in
Order amount
Est. shares
0 shares
Recursion Pharmaceuticals (RXRX) P/E Ratio Historic Data
| Date | Stock price | P/E ratio |
|---|---|---|
| Oct 1, 2025 | $5.10 | -2.86 |
| Sep 2, 2025 | $4.66 | -2.61 |
| Aug 1, 2025 | $5.68 | -3.20 |
| Jul 1, 2025 | $5.13 | -2.89 |
| Jun 2, 2025 | $4.37 | -2.46 |
| May 1, 2025 | $5.50 | -3.31 |
| Apr 1, 2025 | $5.095 | -3.07 |
| Mar 3, 2025 | $6.59 | -3.97 |
| Feb 3, 2025 | $7.25 | -4.75 |
| Jan 2, 2025 | $7.21 | -4.72 |
Recursion Pharmaceuticals (RXRX) End of Year P/E Ratio
| Date | P/E ratio | Change |
|---|---|---|
| 2025 | -3.80 | -14.03% |
| 2024 | -4.42 | -34.32% |
| 2023 | -6.73 | +25.56% |
| 2022 | -5.36 | -65.49% |
| 2021 | -15.53 | — |
FAQs About Recursion Pharmaceuticals (RXRX) P/E ratio
The latest P/E ratio of Recursion Pharmaceuticals (RXRX) is -3.80, as of Oct 15, 2025. This is calculated based on its current stock price and earnings per share (EPS).
Recursion Pharmaceuticals’s last 12-month average P/E ratio is -3.56, compared to its current P/E ratio of -3.80. This reflects a increase of 6.74%.
Recursion Pharmaceuticals’s current P/E ratio of -3.80 is higher than its last 12-month average P/E of -3.56. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
Recursion Pharmaceuticals’s average P/E ratio over the last 3 years is -4.95. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
Recursion Pharmaceuticals’s average P/E ratio over the last 5 years is -4.58. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.